Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells

Endocrine-Related Cancer

Volumn 20, Issue 3, 2013, Pages 371-381

  Segolene Hescot ^a,b   Slama, Abdelhamid ^c   Lombès, Anne ^d   Paci, Angelo ^e   Remy, Hervé ^e   Leboulleux, Sophie ^e   Chadarevian, Rita ^f   Trabado, Séverine ^a,b,c   Amazit, Larbi ^a,b   Young, Jacques ^a,b,c   Baudin, Eric ^a,b,e   Lombès, Marc ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c BICÊTRE HOSPITAL   (France)

^d INSTITUT COCHIN   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f Laboratoire HRA Pharma   (France)

Author keywords

Adrenocortical carcinoma; Cytochrome c oxidase; Mitochondria; Mitotane; O,p' DDD

Indexed keywords

ALDOSTERONE SYNTHASE; CELL NUCLEUS DNA; CHOLESTEROL MONOOXYGENASE (SIDE CHAIN CLEAVING); CYTOCHROME C OXIDASE; HYDROXYPROGESTERONE; MITOCHONDRIAL DNA; MITOTANE; PROSTAGLANDIN SYNTHASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); UBIQUINOL CYTOCHROME C REDUCTASE;

ADRENAL CORTEX CELL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; HORMONE RELEASE; HUMAN; IC 50; RESPIRATORY CHAIN; STEROID RELEASE; STEROIDOGENESIS;

ADRENOCORTICAL CARCINOMA; CYTOCHROME C OXIDASE; MITOCHONDRIA; MITOTANE; O,P'-DDD;

17-ALPHA-HYDROXYPROGESTERONE; ADRENAL CORTEX; ANTINEOPLASTIC AGENTS, HORMONAL; CELL LINE; DNA, MITOCHONDRIAL; ELECTRON TRANSPORT; ELECTRON TRANSPORT COMPLEX IV; HUMANS; HYDROCORTISONE; MITOCHONDRIA; MITOTANE;

EID: 84879479863     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-12-0368     Document Type: Article

References (43)

1. Agier V, Oliviero P, Laine J, L'Hermitte-Stead C, Girard S, Fillaut S, Jardel C, Bouillaud F, Bulteau AL & Lombes A 2012 Defective mitochondrial fusion, altered respiratory function, and distorted cristae structure in skin fibroblasts with heterozygous OPA1 mutations. Biochimica et Biophysica Acta 1822 1570-1580. (doi:10.1016/j.bbadis.2012.07.002)
2. Asp V, Ulleras E, Lindstrom V, Bergstrom U, Oskarsson A & Brandt I 2012 Biphasic hormonal responses to the adrenocorticolytic DDT metabolite 3-methylsulfonyl-DDE in human cells. Toxicology and Applied Pharmacology 242 281-289. (doi:10.1016/j.taap.2009.10.018)
3. Assie G, Antoni G, Tissier F, Caillou B, Abiven G, Gicquel C, Leboulleux S, Travagli JP, Dromain C, Bertagna X et al. 2007 Prognostic parameters of metastatic adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism 92 148-154. (doi:10.1210/jc.2006-0706)
4. Baudin E, Pellegriti G, Bonnay M, Penfornis A, Laplanche A, Vassal G & Schlumberger M 2001 Impact of monitoring plasma 1,1- dichlorodiphenildichloroethane (o, p'DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 92 1385-1392. (doi:10.1002/1097- 0142(20010915)92:6!1385::AID-CNCR1461O3.0.CO;2-2)
5. Baudin E, Leboulleux S, Al Ghuzlan A, Chougnet C, Young J, Deandreis D, Dumont F, Dechamps F, Caramella C, Chanson P et al. 2011 Therapeutic management of advanced adrenocortical carcinoma:what doweknowin 2011? Hormones & Cancer 2 363-371. (doi:10.1007/s12672-011-0094-2)
6. Bergenstal DM & Dao TL 1953 Management of Addison's disease in adrenalectomized patients. Bulletin of the New York Academy of Medicine 29 295-306.
7. Berruti A 2012 Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 23 (supplement 7) 131-138.
8. Cai W, Benitez R, Counsell RE, Djanegara T, Schteingart DE, Sinsheimer JE & Wotring LL 1995 Bovine adrenal cortex transformations of mitotane [1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane; o, p'-DDD] and its p, p'- and m, p'-isomers. Biochemical Pharmacology 49 1483-1489. (doi:10.1016/0006-2952(95)00028-X)
9. Cai W, Counsell RE, Schteingart DE, Sinsheimer JE, Vaz AD & Wotring LL 1997 Adrenal proteins bound by a reactive intermediate of mitotane. Cancer Chemotherapy and Pharmacology 39 537-540. (doi:10.1007/s002800050610)
10. Chen H & Chan DC 2010 Physiological functions of mitochondrial fusion. Annals of the New York Academy of Sciences 1201 21-25. (doi:10.1111/j.1749-6632.2010.05615.x)
11. Chen H, Vermulst M, Wang YE, Chomyn A, Prolla TA, McCaffery JM & Chan DC 2010 Mitochondrial fusion is required for mtDNA stability in skeletal muscle and tolerance of mtDNA mutations. Cell 141 280-289. (doi:10.1016/j.cell.2010. 02.026)
12. Chretien D, Benit P, Chol M, Lebon S, Rotig A, Munnich A & Rustin P 2003 Assay of mitochondrial respiratory chain complex I in human lymphocytes and cultured skin fibroblasts. Biochemical and Biophysical Research Communications 301 222-224. (doi:10.1016/S0006-291X(02)03016-4)
13. Costa R, Wesolowski R & Raghavan D 2011 Chemotherapy for advanced adrenal cancer: improvement from a molecular approach? BJU International 108 1546-1554. (doi:10.1111/j.1464-410X.2011.10464.x)
14. Duarte A, Poderoso C, Cooke M, Soria G, Maciel FC, Gottifredi V & Podesta EJ 2012 Mitochondrial fusion is essential for steroid biosynthesis. PLoS ONE 7 e45829. (doi:10.1371/journal.pone.0045829)
15. van Erp NP, Guchelaar HJ, Ploeger BA, Romijn JA, Hartigh J & Gelderblom H 2011 Mitotane has a strong and a durable inducing effect on CYP3A4 activity. European Journal of Endocrinology 164 621-626. (doi:10.1530/EJE-10- 0956)
16. Fassnacht M & Allolio B 2009 Clinical management of adrenocortical carcinoma. Best Practice & Research. Clinical Endocrinology & Metabolism 23 273-289. (doi:10.1016/j.beem.2008.10.008)
17. Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C, Lacroix A, Jarzab B et al. 2012 Combination chemotherapy in advanced adrenocortical carcinoma. New England Journal of Medicine 366 2189-2197. (doi:10.1056/NEJMoa1200966)
18. Fedeles BI, Zhu AY, Young KS, Hillier SM, Proffitt KD, Essigmann JM & Croy RG 2011 Chemical genetics analysis of an aniline mustard anticancer agent reveals complex I of the electron transport chain as a target. Journal of Biological Chemistry 286 33910-33920. (doi:10.1074/jbc. M111.278390)
19. Haak HR, Hermans J, van de Velde CJ, Lentjes EG, Goslings BM, Fleuren GJ & Krans HM 1994 Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. British Journal of Cancer 69 947-951. (doi:10.1038/bjc.1994.183)
20. Hermsen IG, Fassnacht M, Terzolo M, Houterman S, den Hartigh J, Leboulleux S, Daffara F, Berruti A, Chadarevian R, Schlumberger Met al. 2011 Plasma concentrations of o, p'DDD, o, p'DDA, and o, p'DDE as predictors of tumor response tomitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. Journal of Clinical Endocrinology and Metabolism 96 1844-1851. (doi:10.1210/jc.2010-2676)
21. Icard P, Goudet P, Charpenay C, Andreassian B, Carnaille B, Chapuis Y, Cougard P, Henry JF & Proye C 2001 Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons Study Group. World Journal of Surgery 25 891-897. (doi:10.1007/s00268-001-0047-y)
22. Kaminsky N, Luse S & Hartroft P 1962 Ultrastructure of adrenal cortex of the dog during treatment with DDD. Journal of the National Cancer Institute 29 127-159.
23. Kroiss M, Quinkler M, Lutz WK, Allolio B & Fassnacht M 2011 Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. Clinical Endocrinology 75 585-591. (doi:10.1111/j.1365-2265.2011.04214.x)
24. Kroiss M, Quinkler M, Johanssen S, van Erp NP, Lankheet N, Pollinger A, Laubner K, Strasburger CJ, Hahner S, Muller HH et al. 2012 Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial. Journal of Clinical Endocrinology and Metabolism 97 3495-3503. (doi:10.1210/jc.2012-1419)
25. Liesa M, Palacin M & Zorzano A 2009 Mitochondrial dynamics in mammalian health and disease. Physiological Reviews 89 799-845. (doi:10.1152/physrev.00030.2008)
26. Lin CW, Chang YH & Pu HF 2012 Mitotane exhibits dual effects on steroidogenic enzymes gene transcription under basal and cAMP-stimulating microenvironments in NCI-H295 cells. Toxicology 298 14-23. (doi:10.1016/j.tox. 2012.04.007)
27. Lindhe O, Skogseid B & Brandt I 2002 Cytochrome P450-catalyzed binding of 3-methylsulfonyl-DDE and o, p'-DDD in human adrenal zona fasciculata/reticularis. Journal of Clinical Endocrinology and Metabolism 87 1319-1326. (doi:10.1210/jc.87.3.1319)
28. Lughezzani G, Sun M, Perrotte P, Jeldres C, Alasker A, Isbarn H, Budaus L, Shariat SF, Guazzoni G, Montorsi F et al. 2010 The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation. European Journal of Cancer 46 713-719. (doi:10.1016/j.ejca.2009.12.007)
29. Lund BO & Lund J 1995 Novel involvement of a mitochondrial steroid hydroxylase (P450c11) in xenobiotic metabolism. Journal of Biological Chemistry 270 20895-20897. (doi:10.1074/jbc.270.36.20895)
30. Malandrino P, Al Ghuzlan A, Castaing M, Young J, Caillou B, Travagli JP, Elias D, de Baere T, Dromain C, Paci A et al. 2010 Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma. Endocrine-Related Cancer 17 797-807. (doi:10.1677/ERC-09-0341)
31. Martinerie L, Viengchareun S, Meduri G, Kim HS, Luther JM & Lombès M 2011 Aldosterone postnatally, but not at birth, is required for optimal induction of renal mineralocorticoid receptor expression and sodium reabsorption. Endocrinology 152 2483-2491. (doi:10.1210/en.2010-1460)
32. Martz F & Straw JA 1977 The in vitro metabolism of 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane (o, p'-DDD) by dog adrenal mitochondria and metabolite covalent binding to mitochondrial macromolecules: a possible mechanism for the adrenocorticolytic effect. Drug Metabolism and Disposition 5 482-486.
33. Nijtmans LG, Artal SM, Grivell LA & Coates PJ 2002a The mitochondrial PHB complex: roles in mitochondrial respiratory complex assembly, ageing and degenerative disease. Cellular and Molecular Life Sciences 59 143-155. (doi:10.1007/s00018-002-8411-0)
34. Nijtmans LG, Henderson NS & Holt IJ 2002b Blue native electrophoresis to study mitochondrial and other protein complexes. Methods 26 327-334. (doi:10.1016/S1046-2023(02)00038-5)
35. Rustin P, Chretien D, Bourgeron T, Gerard B, Rotig A, Saudubray JM & Munnich A 1994 Biochemical and molecular investigations in respiratory chain deficiencies. Clinica Chimica Acta 228 35-51. (doi:10.1016/0009-8981(94)90055-8)
36. Scatena R 2012 Mitochondria and drugs. Advances in Experimental Medicine and Biology 942 329-346. (doi:10.1007/978-94-007-2869-1-15)
37. Schteingart DE 2007 Adjuvant mitotane therapy of adrenal cancer - use and controversy. New England Journal of Medicine 356 2415-2418. (doi:10.1056/NEJMe078087)
38. Schteingart DE, Sinsheimer JE, Counsell RE, Abrams GD, McClellan N, Djanegara T, Hines J, Ruangwises N, Benitez R & Wotring LL 1993 Comparison of the adrenalytic activity of mitotane and a methylated homolog on normal adrenal cortex and adrenal cortical carcinoma. Cancer Chemotherapy and Pharmacology 31 459-466. (doi:10.1007/BF00685036)
39. Srivastava S, Diaz F, Iommarini L, Aure K, Lombes A & Moraes CT 2009 PGC-1a/b induced expression partially compensates for respiratory chain defects in cells from patients with mitochondrial disorders. Human Molecular Genetics 18 1805-1812. (doi:10.1093/hmg/ddp093)
40. Stigliano A, Cerquetti L, Borro M, Gentile G, Bucci B, Misiti S, Piergrossi P, Brunetti E, Simmaco M & Toscano V 2008 Modulation of proteomic profile in H295R adrenocortical cell line induced by mitotane. Endocrine-Related Cancer 15 1-10. (doi:10.1677/ERC-07-0003)
41. Viengchareun S, Caron M, Auclair M, Kim MJ, Frachon P, Capeau J, Lombès M & Lombes A 2007 Mitochondrial toxicity of indinavir, stavudine and zidovudine involves multiple cellular targets in white and brown adipocytes. Antiviral Therapy 12 919-929.
42. Wangberg B, Khorram-Manesh A, Jansson S, Nilsson B, Nilsson O, Jakobsson CE, Lindstedt S, Oden A & Ahlman H 2010 The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane. Endocrine-Related Cancer 17 265-272. (doi:10.1677/ERC-09-0190)
43. Zsippai A, Szabo DR, Tombol Z, Szabo PM, Eder K, Pallinger E, Gaillard RC, Patocs A, Toth S, Falus A et al. 2012 Effects of mitotane on gene expression in the adrenocortical cell line NCI-H295R: a microarray study. Pharmacogenomics 13 1351-1361. (doi:10.2217/pgs.12.116)